Nolan D - Search Results

1

New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.

Pavlos R, Deshpande P, Chopra A, Leary S, Strautins K, Nolan D, Thorborn D, Shaefer M, Rauch A, Dunn D, Montaner J, Rachlis A, Almeida CA, Choo L, James I, Redwood AJ, Li Y, Gaudieri S, Mallal SA, Phillips EJ. Pavlos R, et al. Among authors: nolan d. Hum Immunol. 2020 Jun;81(6):300-304. doi: 10.1016/j.humimm.2020.02.011. Epub 2020 Mar 12. Hum Immunol. 2020. PMID: 32173028 Free PMC article.

2

Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.

Martin A, Nolan D, Almeida CA, Rauch A, Mallal S. Martin A, et al. Among authors: nolan d. Pharmacogenomics. 2006 Jan;7(1):15-23. doi: 10.2217/14622416.7.1.15. Pharmacogenomics. 2006. PMID: 16354121 Review.

3

A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.

Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S. Martin AM, et al. Among authors: nolan d. Pharmacogenet Genomics. 2006 May;16(5):353-7. doi: 10.1097/01.fpc.0000197468.16126.cd. Pharmacogenet Genomics. 2006. PMID: 16609367

4

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.

Lucas A, Nolan D, Mallal S. Lucas A, et al. Among authors: nolan d. J Antimicrob Chemother. 2007 Apr;59(4):591-3. doi: 10.1093/jac/dkl557. Epub 2007 Feb 22. J Antimicrob Chemother. 2007. PMID: 17317695

5

Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, James I, McCluskey J, Phillips E, Landay A, Mallal S. Martin AM, et al. Among authors: nolan d. AIDS. 2007 Jun 19;21(10):1233-44. doi: 10.1097/QAD.0b013e3280119579. AIDS. 2007. PMID: 17545699

6

Cytokine profiling in abacavir hypersensitivity patients.

Almeida CA, Martin AM, Nolan D, Lucas A, Cameron PU, James I, Phillips E, Mallal S. Almeida CA, et al. Among authors: nolan d. Antivir Ther. 2008;13(2):281-8. Antivir Ther. 2008. PMID: 18505179

7

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA. John M, et al. J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33. doi: 10.1097/00126334-200305010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12792352 Clinical Trial.

8

Clinical and immunogenetic correlates of abacavir hypersensitivity.

Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH. Phillips EJ, et al. AIDS. 2005 Jun 10;19(9):979-81. doi: 10.1097/01.aids.0000171414.99409.fb. AIDS. 2005. PMID: 15905681

9

Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?

Nolan D, Gaudieri S, Mallal S. Nolan D, et al. J HIV Ther. 2003 May;8(2):36-41. J HIV Ther. 2003. PMID: 12838163 Review.

10

Thymidine analogue-sparing highly active antiretroviral therapy (HAART).

Nolan D, Mallal S. Nolan D, et al. J HIV Ther. 2003 Feb;8(1):2-6. J HIV Ther. 2003. PMID: 12840707 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

639 results

Search Page

Filters